5/18/2020 9:35:45 PM
Bluebird Bio Prices Underwritten Public Offering Of 9.09 Mln Shares At $55.00/shr
5/18/2020 7:03:37 AM
Bluebird Bio Commences Public Offering Of $400 Mln Shares
5/11/2020 7:39:05 AM
Bluebird Bio Amends Existing Co-promotion/co-development Agreement With Bristol Myers Squibb
3/26/2020 7:36:03 AM
Bluebird Bio Issues Update On Business Operations And Clinical Program Development
1/13/2020 5:02:46 AM
Bluebird Bio Announces Launch In Germany Of ZYNTEGLO
11/12/2019 7:15:34 AM
Bluebird Bio And Forty Seven Enter Into Research Collaboration
10/22/2019 7:45:50 AM
Bluebird Bio: EMA Approves Refined Commercial Manufacturing
Specifications For ZYNTEGLO
10/9/2019 8:15:00 AM
Bluebird Bio And Novo Nordisk Enter Research Collaboration
9/27/2019 7:04:09 AM
Bluebird Bio Appoints William Sellers To Board
9/18/2019 9:28:43 AM
Bluebird Bio Presents Updated Results From Clinical Development Program For Lenti-D Gene Therapy
5/15/2019 6:55:34 AM
Wedbush Cuts bluebird bio Inc. (BLUE) To Neutral From Outperform With $131 Down From $166 Price Target
2/11/2019 6:36:01 AM
Bluebird Bio Names Chip Baird CFO
1/7/2019 8:13:34 AM
Bluebird Bio And Inhibrx Collaborate To Research, Develop And Commercialize CAR T Cell Immunotherapies
12/3/2018 9:32:36 PM
Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Sickle Cell Disease
12/3/2018 9:32:23 PM
Bluebird Bio Presents New Data For LentiGlobin Gene Therapy In Transfusion Dependent ?-Thalassemia